1. Home
  2. > Pharmaceutical
  3. > Therapy Market Trends
Immuno-oncology: Focus on Developments and Opportunities in Immune Checkpoint Modulators

Immuno-oncology: Focus on Developments and Opportunities in Immune Checkpoint Modulators

  • March 2020
  • 141 pages
  • ID: 5885802
  • Format: PDF
  • GlobalData

Summary

Table of Contents

Search Inside

Immuno-oncology: Focus on Developments and Opportunities in Immune Checkpoint Modulators

Summary
Immuno-oncology (IO) is the study and development of specialized treatments or immunotherapies for cancer to overcome the immune evasion mechanisms and to stimulate and enhance the immune system’s combat against cancer cells.

This report focuses on immune checkpoint modulators and provides an overview of the current and emerging key products and players within the 8MM (France, Germany, Italy, Spain, UK, US, Japan, China), main unmet needs; R&D challenges, strategies and opportunities; and clinical development trends.The report also includes competitive analysis of marketed products and a tabular analysis of key checkpoint targets and indications investigated in clinical trials.

In addition, the report also provides an overview and critical assessment of the future landscape including bispecific antibodies, predictive/prognostic biomarkers and microbiome.

Key Highlights
- Although ICIs work in some tumors such as lung cancer and melanoma, the majority of cancers fail to respond to ICIs, mainly due to various tumor- and immune-related factors.
- These tumor types are refractory, benefitting the least from available therapies. Remission rates in all tumors are high, which can result in secondary resistance to ICIs.
- The understanding of endogenous resistance mechanisms is poor and ICI monotherapy has not been able to overcome issues related to secondary resistance.
- None of the current biomarkers used in development and in clinical practice are sensitive or accurate enough.
- Without robust predictive/prognostic biomarkers, it is difficult to execute effective patient segmentation in clinical trials, match the best drugs for combination therapies, or predict and proactively manage side effects that might arise due to a treatment.
- Lack of robust, predictive biomarkers creates a bottleneck for companies to develop safer and effective therapies for both small subsets of patients as well as for common tumors.
- Current research in novel checkpoint targets provides possible rationale for addressing primary and secondary resistance in some tumor types.
- In addition to immunotherapy combinations, companies are investigating targeted therapies as possible additions to ICI-based combinations to increase response rates in tumors with known mutations and genetic aberrations.
- In the future, with emerging pharmacological and immune biomarkers, the analyst expects numerous doublet and triplet combination therapies to appear in all lines of treatment.

Key Questions Answered
- What are the main types of immune checkpoint modulators?
- What are the key marketed products and agents in development in the 8MM?
- What are the key checkpoint targets and indications that are being investigated?
- What are the main unmet needs in immune checkpoint inhibitors (ICIs)?
- What are the main R&D challenges and strategies in ICIs?
- What development trends exist or are anticipated in ICI-based therapies?
- What are the opportunities in biomarker development and microbiome studies?

Scope
- Quotes from 10 US-, 5EU-, and Japan-based key opinion leaders
- Robust analysis of high-prescriber survey conducted with 94 oncologists
- Summary of main types of immune checkpoint modulators
- Competitive Analysis of key marketed/pipeline products in 8MM
- Overview and critical analysis of main unmet needs, R&D challenges and strategies.
- Overview and analysis of development opportunities in current and emerging clinical targets, and novel combinations across key indications.
- Overview of biomarker technologies and microbiome
- Call-outs of key information and details
- Insight from specialist oncology analysts

Reasons to Buy
The report will enable you to -
- Develop business strategies by understanding the trends shaping and driving ICI-based therapies in the 8MM.
- Drive revenues by understanding the key trends, innovative combination strategies and indications likely to impact the utility of immune checkpoint modulators in the future.
- Design your development strategy through a review of potential novel targets or combinations across indications.
- Understand the challenges and strategies impacting the development of immune checkpoint modulators in preclinical studies and clinical trials.
- Organize your sales and marketing efforts by understanding ICI-based combination approaches across indications that present maximum opportunities for consolidations, investments, and strategic partnerships.
- Develop strategies by understanding expert perceptions of unmet needs in key indications in oncology, and the potential for immune checkpoint modulators to meet those needs.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Global Head And Neck Cancer Therapeutics Market Size, Share & Industry Trends Analysis Report By Therapy Type, By Route of Administration, By Distribution Channel, By Regional Outlook and Forecast, 2022 - 2028

  • $ 3600
  • November 2022
  • 206 pages

The Global Head And Neck Cancer Therapeutics Market size is expected to reach $2.5 billion by 2028, rising at a market growth of 12.3% CAGR during the forecast period. The majority of malignancies that ...

  • World
  • North America
  • Ear, Nose, And Throat Medicine
  • Oncology
  • Industry analysis
  • Cause-Specific Mortality Rate

ref:plp2020

Reportlinker.com © Copyright 2023. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on